Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 21:12:5.
doi: 10.1186/1475-2867-12-5.

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

Elizabeth Hijona  1 , Jesús María Banales, Lander Hijona, Juan Francisco Medina, Juan Arenas, Marta Herreros-Villanueva, Pablo Aldazabal, Luis Bujanda
Affiliations

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

Elizabeth Hijona et al. Cancer Cell Int. .

Abstract

Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.

Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.

Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).

Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Animal model.
Figure 2
Figure 2
Levels of proliferation in PLC cells.
Figure 3
Figure 3
Macro and microscopic images of livers from each of the groups.
Figure 4
Figure 4
Expression of PCNA in the different groups.
Figure 5
Figure 5
Expression of MAT1A in the different groups.
Figure 6
Figure 6
Levels of AST, ALT, GGT and ALP in the different groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Parkin DM, Bray F, Ferlay J, Pisan P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:143–156. - PubMed
    1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750. doi: 10.1056/NEJM199903113401001. - DOI - PubMed
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917. doi: 10.1016/S0140-6736(03)14964-1. - DOI - PubMed
    1. Lang L. FDA approves sorafenib for patients with inoperavle liver cancer. Gastroenterology. 2008;134:379. - PubMed
    1. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y. et al.Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomised controlled trial. Br J Cancer. 2001;84:886–891. doi: 10.1054/bjoc.2000.1716. - DOI - PMC - PubMed

LinkOut - more resources